In validation experiments, four structurally distinct CCBs (amlodipine besylate, felodipine, manidipine dichloride and cilnidipine) were demonstrated to significantly reduce the number of MYO10-induced filopodia in breast cancer cells as efficiently as a PI3K inhibitor (positive control to block MYO10 activity16), whereas a treatment with zonisamide (inhibits t-type calcium channels, voltage-gated sodium channels and carbonic anhydrase) or bumetanide (inhibits the Na+/K+/2Cl− cotransporter) failed to affect filopodia number (Fig. 1a). Here, SLC12A1 is linked to breast cancer.